Last reviewed · How we verify
EU-Neulasta
At a glance
| Generic name | EU-Neulasta |
|---|---|
| Also known as | Recombinant human granulocyte colony-stimulating factor (G-CSF), Pegfilgrastim |
| Sponsor | Mylan Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (PHASE2)
- Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta (PHASE1)
- A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EU-Neulasta CI brief — competitive landscape report
- EU-Neulasta updates RSS · CI watch RSS
- Mylan Inc. portfolio CI